All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

MajesTEC-5: A phase II trial of Tal-DR induction for transplant-eligible NDMM

By Megan Moore

Share:

Nov 19, 2026

Learning objective: After reading this article, learners will be able to cite a new clinical development in newly diagnosed multiple myeloma.


Results from the phase II MajesTEC-5 trial (NCT05695508), evaluating talquetamab + daratumumab + lenalidomide (Tal-DR) as induction therapy in patients with transplant-eligible newly diagnosed multiple myeloma (TE-NDMM), were presented by Leo Rasche at the 23rd International Myeloma Society (IMS) Annual Meeting and Exposition, September 23–26, 2026, Glasgow, UK. The primary endpoints were adverse events (AEs) and serious AEs.

Key data: At a median follow-up of 12.5 months, Grade 3/4 treatment-emergent AEs (TEAEs) occurred in 65% of patients receiving Tal-DR (n = 20), including neutropenia (30%), leukopenia (30%), and infections (20%). Cytokine release syndrome (CRS) occurred in 70% of patients; all events were Grade 1/2 and resolved without treatment discontinuation. No cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were reported. Taste changes occurred in 80% of patients, rash-related AEs in 55%, and nail-related AEs in 20%. Talquetamab was discontinued due to TEAEs in 20% of patients. Stem cell mobilization was undertaken in 95% of patients, and 90% underwent autologous stem cell transplantation (ASCT). The overall response rate (ORR) post ASCT/pre-maintenance was 90%, with complete response (CR) or better and very good partial response (VGPR) or better rates of 70% and 85%, respectively. Measurable residual disease (MRD) negativity at 10−5 was observed in 90% of patients.

Key learning: In this phase II trial, Tal-DR induction in patients with TE-NDMM was associated with high response rates and a high rate of MRD negativity, supporting further evaluation of Tal-DR in this patient population.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.